Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on July 27th, 2018%
Two new crowdsourcing competitions announced this week are seeking ideas on broadening the scope of drugs being developed for companion animals, and making drugs easier to give to pets and farm animals. . . . → Read More: Challenges Seek Solutions for Chronic Diseases, Oral Drugs in Animals
By Alan, on July 27th, 2018%
A lab in the U.K. developed a system for discovering new therapies that identify therapy targets linked to enzymes, some found in neurodegenerative diseases, previously considered too difficult to address. . . . → Read More: Drug Discovery System Designed to Identify Difficult Targets
By Alan, on July 27th, 2018% This article will draw your attention towards some of the essentials steps you need to take, and how much investment you’re going to require. . . . → Read More: Launching A Cosmetics Brand Is Not As Easy As You Think
By Alan, on July 26th, 2018%
An experimental drug designed to silence a protein associated with inherited forms of amyotrophic lateral sclerosis, or ALS, is shown in tests with lab rodents to extend survival and reverse some neuromuscular damage. . . . → Read More: Experimental Drug Extends Survival, Reverses Inherited ALS Damage
By Alan, on July 26th, 2018%
BASF and a research institute at University of California in Davis are investigating complex sugars found in human breast milk, and their role in maintaining healthy gut microbes. . . . → Read More: BASF, UC-Davis Partner on Human Milk Sugars
By Alan, on July 26th, 2018% It can’t be ignored that employees can cause or be part of the biggest headaches that you’ll face as a business owner. . . . → Read More: Meds for Those Employee Headaches
By Alan, on July 25th, 2018%
A spin-off enterprise from Case Western Reserve University is developing therapies designed to restore the myelin sheath around nerve cells destroyed in multiple sclerosis and other neurological disorders. . . . → Read More: Univ. Spin-Off Developing Myelin Disease Treatments Unveiled
By Alan, on July 25th, 2018%
Consumer genetics company 23andMe signed a 4-year agreement to help drug maker GlaxoSmithKline find more precise drug targets and recruit clinical trial participants likely to respond to treatments. . . . → Read More: GSK, 23andMe Ink Precision Meds Discovery Deal
By Alan, on July 25th, 2018% It’s not rare to find a marketing executive poring over analytic software, trying to figure out who bounced and why. . . . → Read More: Enjoy Big Data Success With These Guidelines
By Alan, on July 24th, 2018%
Drug maker Merck is acquiring the rights to therapies for cancer and autoimmune disorders based on a technology for developing synthetic proteins from a process that bypasses live cells. . . . → Read More: Merck, Biopharma Partner on Cell-Free Immune System Therapies
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|